• bitcoinBitcoin(BTC)$64,833.000.39%
  • ethereumEthereum(ETH)$1,820.130.27%
  • tetherTether(USDT)$1.00-0.01%
  • binancecoinBNB(BNB)$596.581.17%
  • usd-coinUSDC(USDC)$1.000.00%
  • rippleXRP(XRP)$0.983.00%
  • solanaSolana(SOL)$74.934.90%
  • tronTRON(TRX)$0.3077780.85%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.01-2.86%
  • HyperliquidHyperliquid(HYPE)$69.720.90%
  • zcashZcash(ZEC)$962.646.97%
  • moneroMonero(XMR)$509.883.52%
  • dogecoinDogecoin(DOGE)$0.0598991.96%
  • leo-tokenLEO Token(LEO)$9.311.65%
  • USDSUSDS(USDS)$1.000.02%
  • whitebitWhiteBIT Coin(WBT)$62.630.25%
  • chainlinkChainlink(LINK)$9.281.81%
  • cardanoCardano(ADA)$0.1546481.19%
  • stellarStellar(XLM)$0.1413952.83%
  • Ethena USDeEthena USDe(USDE)$1.00-0.01%
  • daiDai(DAI)$1.00-0.01%
  • nearNEAR Protocol(NEAR)$3.377.06%
  • bitcoin-cashBitcoin Cash(BCH)$211.661.75%
  • litecoinLitecoin(LTC)$45.181.70%
  • CantonCanton(CC)$0.082100-0.02%
  • RainRain(RAIN)$0.004568-27.64%
  • avalanche-2Avalanche(AVAX)$7.272.47%
  • uniswapUniswap(UNI)$5.282.10%
  • tether-goldTether Gold(XAUT)$3,827.44-0.40%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.071.80%
  • suiSui(SUI)$0.742.56%
  • USD1USD1(USD1)$1.000.03%
  • Ripple USDRipple USD(RLUSD)$1.000.01%
  • Global DollarGlobal Dollar(USDG)$1.000.01%
  • hedera-hashgraphHedera(HBAR)$0.0581072.01%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.150.15%
  • paypal-usdPayPal USD(PYUSD)$1.000.01%
  • BittensorBittensor(TAO)$197.633.52%
  • crypto-com-chainCronos(CRO)$0.0442492.18%
  • shiba-inuShiba Inu(SHIB)$0.0000040.62%
  • quant-networkQuant(QNT)$155.070.97%
  • MemeCoreMemeCore(M)$0.893.88%
  • Circle USYCCircle USYC(USYC)$1.140.01%
  • Spiko Amundi Overnight Swap Fund (EUR)Spiko Amundi Overnight Swap Fund (EUR)(EURSAFO)$1.12-0.11%
  • okbOKB(OKB)$86.601.19%
  • aaveAave(AAVE)$112.153.33%
  • pax-goldPAX Gold(PAXG)$3,831.46-0.35%
  • Falcon USDFalcon USD(USDF)$1.000.10%
  • United StablesUnited Stables(U)$1.00-0.04%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

Vivek Ramaswamy-founded company to sell drug in $7B deal

July 14, 2023
in Business
Reading Time: 7 mins read
A A
Vivek Ramaswamy-founded company to sell drug in B deal
ShareShareShareShareShare

A pharmaceutical company founded by Republican presidential candidate Vivek Ramaswamy is reportedly in talks to sell an experimental drug in a deal that could be valued at more than $7 billion.

Roivant Sciences, which Ramaswamy started in 2014, has worked to commercialize drugs held up in development by acquiring them and creating subsidiaries to develop them, according to The Wall Street Journal.

YOU MAY ALSO LIKE

Costco shoppers panic-buy water, generators after freak outages

Suspected Chinese spy Alice Huang’s husband Kang Wei ran state-backed AI empire: report

In February, the same day he publicly announced his White House bid, Ramaswamy revealed he was stepping down from Roivant’s board to focus on his 2024 presidential campaign.

Months before, in November, Roivant secured the rights to an in-trial medication that can treat debilitating stomach diseases like Chron’s and ulcerative colitis.

Switzerland-based Roche — the fifth-largest pharmaceutical company in the world — is reportedly ready to dish out billions to secure those rights, people familiar with the matter told The Journal.

If the deal isn’t hijacked by another potential buyer, a Roivant-Roche deal could be sealed in the coming days, The Journal reported.


Roivant Sciences, a pharmaceutical company founded by Vivek Ramaswamy in 2014, is in talks to sell an experimental drug that can treat debilitating stomach diseases in a deal that could be valued at more than $7 billion.
Getty Images

Roivant acquired its stomach disease treatment from a deal with Pfizer late last year.

Roivant formed a new subsidiary, called Telavant, to fund the development of the drug, which goes by RVT-3101, according to The Journal.

RVT-3101 is in Phase 3 — the final phase — of testing, and has reported positive results up until this point.

In a statement released in January, Roivant reported that 32% of patients involved in RVT-3101’s trial achieved clinical remission.

“Across all doses and patient groups, RVT-3101 was well tolerated and showed a favorable safety profile,” it added.

Pfizer still has a 25% stake in Televant, and has commercial rights outside the US and Japan. It was unclear what would happen to Pfizer’s part-ownership should the deal close.

RVT-3101 contains an anti-TL1A antibody, which has previously been used to treat intestinal inflammation and has since become a highly-coveted asset in the race to cure bowel diseases.

Last month, Merck & Co. agreed to pay $10.8 billion to buy Prometheus Biosciences for a rival therapy that also treats ulcerative colitis, The Journal reported.

The deal came just months after Roivant secured the rights to the drug in November.

Merck reportedly beat out competitors AbbVie and Bristol Myers Squibb from scooping up Prometheus.


Roche, the fifth-largest pharmaceutical company in the world, is the brand behind the multibillion-dollar bid on the drug, called RVT-3101.
Roche, the fifth-largest pharmaceutical company in the world, is the brand behind the multibillion-dollar bid on the drug, called RVT-3101.
SOPA Images/LightRocket via Getty Images

In December, Amgen agreed to buy Horizon Therapeutics in another multibillion-dollar bet on curing autoimmune diseases.

It was the largest healthcare merger of 2022, with Amgen splashing out $27.8 billion to acquire the Ireland-based biopharmaceutical company, according to The Journal.

Should Roivant become the next pharma brand to strike a deal, it would be among the biggest moves by Roche boss Thomas Schinecker since he took the helm of the Swiss life-sciences giant in March, the outlet reported.

The Post has reached out to Roche for comment.

Credit: Source link

ShareTweetSendSharePin

Related Posts

Costco shoppers panic-buy water, generators after freak outages
Business

Costco shoppers panic-buy water, generators after freak outages

November 17, 2026
Suspected Chinese spy Alice Huang’s husband Kang Wei ran state-backed AI empire: report
Business

Suspected Chinese spy Alice Huang’s husband Kang Wei ran state-backed AI empire: report

November 17, 2026
Ford worker fired over cookie sues and claims AI falsely flagged him as thief
Business

Ford worker fired over cookie sues and claims AI falsely flagged him as thief

November 17, 2026
Disgraced ex-Nvidia CEO Jensen Huang to testify before Congress next month
Business

Disgraced ex-Nvidia CEO Jensen Huang to testify before Congress next month

November 17, 2026
Next Post
Why generative AI just hits different – and why organizations need to embrace it now

Why generative AI just hits different – and why organizations need to embrace it now

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
13 Rules for Lending to Family & Friends – Treat It Like a Real Loan

13 Rules for Lending to Family & Friends – Treat It Like a Real Loan

November 14, 2026
U.S. carries out strikes on Iran’s Qeshm Island

U.S. carries out strikes on Iran’s Qeshm Island

November 12, 2026
Deadly Train Crash in Spain; Pretti’s Parents Call Out Feds; Mel Robbins on Stress – Oct. 28

Deadly Train Crash in Spain; Pretti’s Parents Call Out Feds; Mel Robbins on Stress – Oct. 28

November 15, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!